Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rodolfo Hurle

Showing results (41-50 of 183) with videos related to

Pageof 19
Sort By:
European Urology Open Science|August 2, 2021
Long-term Follow-up After En Bloc Transurethral Resection of Non-muscle-invasive Bladder Cancer: Results from a Single-center ExperienceMarco Paciotti, Paolo Casale, Piergiuseppe Colombo, et al.
European Urology Focus|January 10, 2024
The Financial Burden of Guideline-recommended Cancer Medications for Metastatic Urothelial CarcinomaRoberto Contieri, Alberto Martini, Laura S Mertens, et al.
Cancer Medicine|March 12, 2026
Vitamin D and Bladder Cancer Risk: An Umbrella Review and Second Order Meta-AnalysisStefano Mancin, Gaetano Ferrara, Sara Morales Palomares, et al.
Urologic Oncology|July 26, 2011
A randomized phase IIb presurgical study of finasteride vs. low-dose flutamide vs. placebo in men with prostate cancer. Efficacy monitored by karyometryRodolfo Montironi, Peter H Bartels, Andrea DeCensi, et al.
European Urology Oncology|June 1, 2021
Long-term Follow-up and Factors Associated with Active Surveillance Failure for Patients with Non-muscle-invasive Bladder Cancer: The Bladder Cancer Italian Active Surveillance (BIAS) ExperienceRoberto Contieri, Marco Paciotti, Giovanni Lughezzani, et al.
World Journal of Urology|April 3, 2021
Feasibility, safety, and efficacy of ultrasound-guided transperineal laser ablation for the treatment of benign prostatic hyperplasia: a single institutional experienceNicola Frego, Alberto Saita, Paolo Casale, et al.
Frontiers in Oncology|June 6, 2022
Could We Safely Avoid a Second Resection in Selected Patients With T1 Non-Muscle-Invasive Bladder Cancer? Preliminary Results of Cost-Effectiveness Study From HUmanitas New Indications for ReTUR (HuNIRe) Multicenter Prospective TrialRoberto Contieri, Giovanni Lughezzani, Nicolò Maria Buffi, et al.
European Urology Focus|November 11, 2018
Early Catheter Removal After Robot-assisted Radical Prostatectomy: Results from a Prospective Single-institutional Randomized Trial (Ripreca Study)Giuliana Lista, Giovanni Lughezzani, Nicolò Maria Buffi, et al.
Urologic Oncology|September 19, 2019
Predictive factors of the absence of residual disease at repeated transurethral resection of the bladder. Is there a possibility to avoid it in well-selected patients?Francesco Soria, David D'Andrea, Marco Moschini, et al.
Minerva Urology and Nephrology|August 2, 2021
Active surveillance for recurrent non-muscle invasive bladder cancer: which lessons have we learned during COVID-19 pandemic?Marco Paciotti, Roberto Contieri, Vittorio Fasulo, et al.
Pageof 19

Showing results (41-50 of 183) with videos related to

Sort By:
Pageof 19
European Urology Open Science|August 2, 2021
Long-term Follow-up After En Bloc Transurethral Resection of Non-muscle-invasive Bladder Cancer: Results from a Single-center ExperienceMarco Paciotti, Paolo Casale, Piergiuseppe Colombo, et al.
European Urology Focus|January 10, 2024
The Financial Burden of Guideline-recommended Cancer Medications for Metastatic Urothelial CarcinomaRoberto Contieri, Alberto Martini, Laura S Mertens, et al.
Cancer Medicine|March 12, 2026
Vitamin D and Bladder Cancer Risk: An Umbrella Review and Second Order Meta-AnalysisStefano Mancin, Gaetano Ferrara, Sara Morales Palomares, et al.
Urologic Oncology|July 26, 2011
A randomized phase IIb presurgical study of finasteride vs. low-dose flutamide vs. placebo in men with prostate cancer. Efficacy monitored by karyometryRodolfo Montironi, Peter H Bartels, Andrea DeCensi, et al.
European Urology Oncology|June 1, 2021
Long-term Follow-up and Factors Associated with Active Surveillance Failure for Patients with Non-muscle-invasive Bladder Cancer: The Bladder Cancer Italian Active Surveillance (BIAS) ExperienceRoberto Contieri, Marco Paciotti, Giovanni Lughezzani, et al.
World Journal of Urology|April 3, 2021
Feasibility, safety, and efficacy of ultrasound-guided transperineal laser ablation for the treatment of benign prostatic hyperplasia: a single institutional experienceNicola Frego, Alberto Saita, Paolo Casale, et al.
Frontiers in Oncology|June 6, 2022
Could We Safely Avoid a Second Resection in Selected Patients With T1 Non-Muscle-Invasive Bladder Cancer? Preliminary Results of Cost-Effectiveness Study From HUmanitas New Indications for ReTUR (HuNIRe) Multicenter Prospective TrialRoberto Contieri, Giovanni Lughezzani, Nicolò Maria Buffi, et al.
European Urology Focus|November 11, 2018
Early Catheter Removal After Robot-assisted Radical Prostatectomy: Results from a Prospective Single-institutional Randomized Trial (Ripreca Study)Giuliana Lista, Giovanni Lughezzani, Nicolò Maria Buffi, et al.
Urologic Oncology|September 19, 2019
Predictive factors of the absence of residual disease at repeated transurethral resection of the bladder. Is there a possibility to avoid it in well-selected patients?Francesco Soria, David D'Andrea, Marco Moschini, et al.
Minerva Urology and Nephrology|August 2, 2021
Active surveillance for recurrent non-muscle invasive bladder cancer: which lessons have we learned during COVID-19 pandemic?Marco Paciotti, Roberto Contieri, Vittorio Fasulo, et al.
Pageof 19